New Paper Offers Practical Roadmap for Using Real-World Data in FDA Drug Approvals and Label Expansions
Slipstream, a technology consulting partner exclusively focused on life sciences, today announced the publication of a new peer-reviewed paper in Clinical Pharmacology and Therapeutics outlining practical guidance for pharmaceutical and biotech companies seeking to use real-world data to support FDA drug approval or label expansion.
Slipstream Announces New Investment from GreyLion Partners and Denali Growth Partners
Slipstream IT (“Slipstream”), a trusted technology partner serving the pharmaceutical and biopharmaceutical industry, today announced an investment from GreyLion Partners LP (“GreyLion”), a U.S. private equity firm focused on high-growth businesses. The investment complements Slipstream’s existing equity investment from Denali Growth Partners (“DGP”), which also participated alongside GreyLion. The financing will further enable the Company to continue investing in people, systems, and processes, while expanding its offerings in new and existing markets through organic growth and potential add-on acquisitions. Terms of the transaction were not disclosed.
